Clarke Anthony 4
4 · ACHIEVE LIFE SCIENCES, INC. · Filed Aug 3, 2017
Insider Transaction Report
Form 4
Clarke Anthony
DirectorPresident & CSO
Transactions
- Award
Common Stock
2017-08-01+6,364,335→ 6,364,335 total(indirect: By Son) - Award
Common Stock
2017-08-01+4,242,890→ 4,242,890 total(indirect: By Spouse) - Award
Common Stock
2017-08-01+6,364,335→ 6,364,335 total
Footnotes (2)
- [F1]Received in exchange for 1,500 common shares of Achieve Life Science, Inc. ("Achieve") pursuant to the merger between OncoGenex Pharmaceuticals, Inc. ("OncoGenex") and Achieve (the "Merger"). On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect an 11-for-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split").
- [F2]Received in exchange for 1,000 common shares of Achieve pursuant to the Merger between OncoGenex and Achieve. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split.